Prolactin Is THE Root Cause of Hair Loss?! Absci’s New Drug May Prove It — Transcript
Full transcript
- 0:00Decades of research tells us that the
- 0:01hormone DHT is the primary cause of
- 0:04pattern hair loss.
- 0:06But what if that's wrong? This isn't
- 0:08some hypothetical anymore. This is the
- 0:09position of a growing number of
- 0:11researchers, all stemming from the
- 0:14craziest monkey hair regrowth photos I
- 0:16have ever seen. Results achieved with a
- 0:19drug that didn't even touch DHT. Now a
- 0:22similar drug made by Absai, an
- 0:25AI-powered pharmaceutical company, is in
- 0:27phase two clinical trials to put this
- 0:30thesis to the test. I just interviewed
- 0:32the company's founder about their novel
- 0:34drug, their current clinical trials,
- 0:36their forthcoming results, which we'll
- 0:38get a peek at at the end of this year,
- 0:40and whether DHT is the root cause of
- 0:42pattern hair loss, or if perhaps another
- 0:45hormone is actually to blame. One that
- 0:47once we adequately target might unlock
- 0:50unprecedented levels of regrowth. Stick
- 0:52around, we're going to be covering it
- 0:53all, and for those new here, my name is
- 0:55Rob English. I research hair loss, I
- 0:57publish and review scientific papers
- 0:59about hair loss disorders, I serve on
- 1:00the editorial board of a dermatology
- 1:02journal, and I make videos like this for
- 1:04anybody who is fighting hair loss and
- 1:05looking for a path forward based on the
- 1:08evidence.
- 1:13This video is about the company Absai,
- 1:15their novel hair loss drug ABS 201, and
- 1:18the hormone that that drug targets. It's
- 1:21not DHT, it's prolactin. We'll get into
- 1:24what this hormone is, how this drug
- 1:25works, if the hype is real, and
- 1:28never-before-released data from Absai's
- 1:30founder, Shawn McLean, who we actually
- 1:32interviewed for this video. We talked
- 1:34for 2 hours, we asked him some very hard
- 1:36questions. For those short on time,
- 1:38please skip to this timestamp for the
- 1:40key takeaways on prolactin and hair
- 1:42loss, ABS 201, and whether I think this
- 1:45drug will succeed. And for everybody
- 1:47else, stick around. I'm about to tell
- 1:50you a story that is going to sound like
- 1:52a Hollywood hero's journey about hair.
- 1:55And it actually begins nearly a decade
- 1:57ago, not with Abside, but with another
- 1:59pharmaceutical company, Bayer, and an
- 2:01experiment that got some very unexpected
- 2:04results and changed the trajectory of
- 2:06their research project for many years.
- 2:12Back then, Andreas Busch, a researcher
- 2:15at Bayer, wanted to see if lowering
- 2:17prolactin levels might help improve a
- 2:19condition called endometriosis. So, his
- 2:21team set up an experiment in mice
- 2:23[music] and injected them with a drug
- 2:25that Bayer developed that would later be
- 2:26called HMI 115. We'll go deeper into
- 2:30this later, but at this stage, all you
- 2:32need to know is that this is a drug
- 2:34that, once injected, helps to lower
- 2:36levels of prolactin signaling in your
- 2:38cells. After injecting these mice,
- 2:41Andreas saw something unexpected. The
- 2:44mice who received HMI 115, the ones who
- 2:47had lowered prolactin activity, they
- 2:49actually saw faster hair regrowth
- 2:52compared to the mice who received a
- 2:53placebo injection. And so, he took these
- 2:55findings to Bayer and said, "I think we
- 2:57might have something here. I think we
- 2:59might have a candidate for a hair loss
- 3:01treatment." Now, you might be thinking
- 3:02at this stage,
- 3:04"Big deal."
- 3:05And I actually agree, because everything
- 3:07regrows hair on mice. Peppermint oil,
- 3:09copper peptides, sugar molecules, and
- 3:12more often than not, those same
- 3:14interventions inevitably fail to regrow
- 3:17hair appreciably in humans, because mice
- 3:20are not men. Mice don't naturally
- 3:22develop male pattern hair loss. And
- 3:24genetically spliced mice made to mimic
- 3:26that condition, they even still remain
- 3:29terrible proxies for treatment success,
- 3:31because candidly, we don't even know all
- 3:33the genes involved in male pattern hair
- 3:35loss to begin with. For more
- 3:36information, watch our video on evidence
- 3:38quality. Suffice it to say that mouse
- 3:40models rarely translate to human success
- 3:43with respect to androgenic alopecia
- 3:45treatments. But, there is another animal
- 3:47that isn't a human, and it does
- 3:49naturally go bald.
- 3:51Stump-tailed macaques. And while monkeys
- 3:53also aren't men, they tend to fare a bit
- 3:56better, at least as surrogates for
- 3:58research translatability doing
- 4:00treatments on hair loss. And Andreas
- 4:02felt that his mouse model results were
- 4:04strong enough that he convinced Bayer to
- 4:06commission a study on stumptailed
- 4:08[music]
- 4:08macaques. Inject them with prolactin
- 4:11receptor antibodies, monitor to see what
- 4:13happens with their scalps, and see if
- 4:16there truly might be something here. And
- 4:19this is where things get a little wild.
- 4:21Because after 6 months of treatment, the
- 4:24monkeys, they appeared totally fine. So,
- 4:27no issues related to adverse events that
- 4:29we know about, except they had regrown a
- 4:32ton of hair. And all by suppressing
- 4:35prolactin signaling in cells, not by
- 4:38touching DHT. And not only that, but
- 4:40when the monkeys actually were withdrawn
- 4:42from treatment, they were monitored for
- 4:44an additional 4 years, and to
- 4:46everybody's shock, during that time
- 4:48period, they actually continued to
- 4:50regrow hair. And not only that, but the
- 4:53older monkeys' hairs that had turned
- 4:55gray had actually repigmented. They went
- 4:57from gray back to colored. And why do I
- 5:00find this crazy? Because in all other
- 5:02monkey and human hair loss research that
- 5:04I have ever seen, I've first never seen
- 5:07this level of regrowth for hair
- 5:09recovery, and I've never seen this level
- 5:11of hair repigmentation. And in all other
- 5:14monkey and human hair loss research,
- 5:16when a treatment is officially
- 5:18withdrawn, you inevitably lose all the
- 5:21hair that you've regained. But in this
- 5:23study, the opposite happened. Despite
- 5:25the monkeys having stopped treatment,
- 5:28they continued to regrow hair, more and
- 5:30more. They continued to get better hair
- 5:32pigment, better and better. That is
- 5:34crazy. And it's something to get really
- 5:36excited about. And it was these findings
- 5:38that prompted Bayer to license their
- 5:40drug to Hope Medicine and expedite
- 5:43studies in humans. In 2023, a phase 1
- 5:46and phase 2 clinical study was launched,
- 5:49and for the next 12 months, everyone,
- 5:51including me, waited for the results
- 5:53thinking,
- 5:55"This might be it. This could be the
- 5:57breakthrough everybody has been waiting
- 5:59for. This could actually be the thing
- 6:01that takes somebody from nearly fully
- 6:02bald to fully haired." And then,
- 6:07nothing. Nothing. Nothing at all. In
- 6:092024, that research group announced that
- 6:12the phase 2 clinical studies had been
- 6:14completed,
- 6:15and then the company never even bothered
- 6:17submitting the results of the report.
- 6:20And then in 2025, a press release was
- 6:22issued about the phase 1 human study on
- 6:24HMI 115, on a whopping 16 people. The
- 6:28findings? It appeared safe,
- 6:30but it only regrew about 14 hairs per
- 6:32square centimeter. That's a far cry from
- 6:34the 100-plus hairs per square centimeter
- 6:37on average seen in that monkey study.
- 6:40And all of a sudden, enthusiasm
- 6:41surrounding HMI 115, and even
- 6:43prolactin's role in hair loss, all but
- 6:46collapsed. Well,
- 6:48all except for maybe one person, and
- 6:50that was Andreas Busch. He contended
- 6:53that the hypothesis on prolactin and
- 6:55hair loss still could be right, but that
- 6:57the monkey study did not translate to
- 6:59the humans not because of differences in
- 7:02hair loss pathology, but instead because
- 7:05he thought the humans were underdosed.
- 7:09That their prolactin wasn't adequately
- 7:10reduced in the way that it was for the
- 7:12monkeys, and that the pharmacokinetic
- 7:15data later released by Bayer
- 7:16Pharmaceuticals, according to him,
- 7:19actually proved it. And this is where
- 7:21Andreas Busch's journey moves from Bayer
- 7:23to another company, Abside, and from HMI
- 7:26115 to a partnership with Abside's
- 7:29founder, Shawn Maclean, and his research
- 7:32team to develop a better drug, one that
- 7:36fixed the problem in the original study
- 7:38on HMI 115, and one that would finally
- 7:41put to rest the thesis about prolactin
- 7:43whether it was actually at the root
- 7:44cause of hair loss.
- 7:47And this is where our conversation with
- 7:49Shawn McLean begins. I'll present this
- 7:51interview in two stages. First, I'm
- 7:55going to get out of Shawn's way. He has
- 7:57a compelling case to make about
- 7:58prolactin's role in hair loss, ABS-201,
- 8:01their ongoing clinical trials, and that
- 8:03steel man argument deserves to be
- 8:05presented uninterrupted. And only after
- 8:08that will I then show you my questions
- 8:10to Shawn and how that altered aspects of
- 8:13our discussion.
- 8:15>> Prolactin has
- 8:17maybe had a a bad rap and I think it was
- 8:20just due to
- 8:21the naming, you know, prolactin is you
- 8:24know, prolactation. Everyone thinks of
- 8:25it as a
- 8:27lactation hormone or or in women's
- 8:29health. But what you see is that
- 8:32prolactin is expressed all throughout
- 8:35the the body both in females but as well
- 8:39as males. You you actually see it in in
- 8:41the scalp. You see it in the the your
- 8:43joints.
- 8:44You you see it in in in your heart and
- 8:47in your bones. It and it and it plays a
- 8:50really interesting role.
- 8:52>> Shawn is describing our evolving
- 8:54understanding of the hormone prolactin.
- 8:57Originally only seen as a female
- 8:59hormone, researchers have now found that
- 9:01prolactin is actually all over the body
- 9:03in men and in women. And its role in
- 9:06human health is not just relegated to
- 9:08lactation.
- 9:09>> It looks like it sits on this
- 9:11stress inflammatory access, you know, in
- 9:15diseases like endometriosis or even
- 9:18androgenic alopecia it's driving,
- 9:20you know, inflammation. Essentially, we
- 9:23have new work that hasn't been published
- 9:24yet, but it looks like, you know, it
- 9:26does have a role in in in metabolism. I
- 9:28think we're just starting to realize
- 9:30how important prolactin's
- 9:33role is uh, in in both uh, male and
- 9:36females and you know, in in the role of,
- 9:39you know, androgenic alopecia,
- 9:41autoimmune diseases,
- 9:42uh, and, uh, and, and, uh, just a kind
- 9:45of immunology in general.
- 9:47>> So, Shawn sees prolactin as a hormone
- 9:49that's often elevated in conditions
- 9:51linked to inflammation, endometriosis,
- 9:54potentially some metabolic disorders,
- 9:56even androgenic alopecia. And at this
- 9:59stage, it's important to understand how
- 10:01prolactin is even arriving to these
- 10:03sites in the first place. Well, first,
- 10:05prolactin is made by our pituitary
- 10:07gland. That's the pea-sized organ that
- 10:09sits at the base of our brain. And that
- 10:11prolactin will enter our bloodstream and
- 10:13then travel through a highway network to
- 10:15other places in the body, where it can
- 10:18then attach to other organ sites and
- 10:20begin to influence the behavior of those
- 10:23cells. But according to Shawn, that's
- 10:24not the only way that our bodies make
- 10:26prolactin. There's also prolactin that
- 10:29our own organs can manufacture on site.
- 10:32And it's this production of prolactin
- 10:34that varies wildly in individuals. And
- 10:37it means that two people can have the
- 10:39same exact levels of blood prolactin,
- 10:41but then if you actually look at their
- 10:43tissue levels, they can be wildly
- 10:45different.
- 10:46>> So, you have the classical pituitary,
- 10:49um, expression of of prolactin, um, but
- 10:52then you also additionally have, and and
- 10:54a lot of people don't under, uh, or or
- 10:56know this, is that prolactin sits on a,
- 11:00uh, an additional promoter that controls
- 11:03the extra pituitary,
- 11:06um,
- 11:07uh, expression. And so, you could have
- 11:09normal systemic levels of prolactin that
- 11:13come from the pituitary, but it
- 11:15increased level of prolactin,
- 11:18uh, within the scalp. And and it's being
- 11:21driven off of that extra pituitary
- 11:23promoter. And what's really interesting
- 11:24is that the transcriptional, uh, uh,
- 11:29factors that that drive the extra
- 11:31pituitary, uh, um, expression are
- 11:33completely different than what you see
- 11:36in
- 11:37in the pituitary. So, they're completely
- 11:40independent. And I think that that's why
- 11:42for a long time
- 11:45this hasn't come up as a
- 11:48potential, you know, prolactin being a
- 11:49potential cause of of hair loss cuz
- 11:52we've been looking at you know, systemic
- 11:55blood levels
- 11:56versus looking at what is the the actual
- 12:00expression within the scalp. And you can
- 12:02have really high expression in the scalp
- 12:03but have completely normal prolactin
- 12:05levels. One of the things though that we
- 12:07don't really know is that
- 12:09how does systemic prolactin
- 12:13in addition contribute to what's being
- 12:15locally
- 12:17produced as as well. That's one of the
- 12:20you know, factors that we we still don't
- 12:22quite understand.
- 12:23>> Okay, so we see elevated levels of
- 12:25prolactin in organs affected by
- 12:26inflammation and autoimmunity. But just
- 12:29because something is higher in a
- 12:30diseased organ, that does not mean that
- 12:32the thing that's elevated is causing
- 12:34that disease. For a perfect example of
- 12:36this, look at blood levels of C-reactive
- 12:38protein or CRP. CRP is often elevated in
- 12:42people with actively evolving
- 12:44atherosclerosis.
- 12:45And so researchers once wondered if CRP
- 12:47was actually causing that
- 12:49atherosclerosis. But later research was
- 12:51able to tease out that this wasn't the
- 12:53case. That CRP was elevated as a
- 12:56reaction to other inflammatory
- 12:58processes. In other words, it wasn't a
- 13:01cause of the inflammation, it was an
- 13:02effect. It was a surrogate of the
- 13:04inflammation happening. So, in that same
- 13:06vein, what exactly is the evidence that
- 13:08causally links prolactin to androgenetic
- 13:11alopecia? Because I have to be honest
- 13:13with you, at first glance the idea of
- 13:15prolactin causing androgenetic alopecia
- 13:18sounds crazy. Because the name of the
- 13:20condition describes its causes.
- 13:22Androgens, male hormones like DHT, and
- 13:26genetic, your genes. And it's not like
- 13:28somebody just gave this condition this
- 13:30name and called it a day. These causes
- 13:32were established over 100 years of
- 13:35research. Men who can't produce the
- 13:37hormone DHT, they never go bald. When
- 13:40you expose balding sensitive scalp skin
- 13:42to DHT, it damages the hair follicles.
- 13:45And when you lower DHT levels in balding
- 13:48men with drugs like finasteride or
- 13:50dutasteride, 80 to 90% of them will see
- 13:53a slowing, stopping, or partial reversal
- 13:55of their hair loss with results
- 13:57sustaining for decades. So, you have
- 14:00decades of observational, mechanistic,
- 14:03and interventional data that all
- 14:05converge on the hormone DHT causing this
- 14:08condition. So, where on Earth does
- 14:10prolactin fit into this? And
- 14:12interestingly, Shawn doesn't refute
- 14:14DHT's role in androgenetic alopecia. He
- 14:17thinks it's absolutely causal. He just
- 14:19argues that DHT doesn't just magically
- 14:22appear in balding scalps. It increases,
- 14:25in part, because of prolactin. And not
- 14:28only that, but by targeting prolactin,
- 14:31he thinks we might even be able to
- 14:32overcome some of the biggest hurdles
- 14:35that prevent people from getting huge
- 14:37hair recoveries, even after they lower
- 14:39their DHT.
- 14:42>> The name is actually very misleading.
- 14:44Androgenetic alopecia, it implies that
- 14:47it's androgen driven. Yes, androgens are
- 14:49a part of it, but from what we're
- 14:51seeing, prolactin actually sits
- 14:54potentially upstream of the androgen
- 14:57receptor. And we actually even have data
- 14:59that that does show that
- 15:01um prolactin drives uh increase in
- 15:04androgen uh uh transcript. And and so,
- 15:07it does look like it regulates uh the
- 15:10androgen receptor.
- 15:11>> There's a lot to unpack here, but
- 15:13basically Shawn is suggesting that when
- 15:15prolactin arrives to a balding scalp, it
- 15:18activates androgen receptors, which are
- 15:20what cells use to allow hormones like
- 15:23DHT to attach to those cells and then
- 15:25exert their effects. And if I were to
- 15:28brutally simplify the old guard versus
- 15:30new guard or new hypothetical argument
- 15:33for androgenic alopecia, the old
- 15:35argument looks like this.
- 15:37After you hit a certain age, your
- 15:39genetics will cause DHT levels to rise
- 15:42in the scalp and those DHT levels will
- 15:44then cause pattern hair loss.
- 15:46What Sean is saying, it adds a a step
- 15:48right here and a step right here. So, it
- 15:50doesn't nullify decades worth of data.
- 15:52It just adds steps to what's happening
- 15:54and makes the chain of events a little
- 15:56more specific. So, that is the
- 15:57supposition.
- 15:59But, what is the evidence to support
- 16:01that supposition?
- 16:03In our interview, Sean builds his case
- 16:06starting with observational data on
- 16:07genes, prolactin, and severities of
- 16:10balding.
- 16:11>> What we did here was we we took a look
- 16:13at the UK Biobank and
- 16:17evaluated um
- 16:20how changes in prolactin
- 16:24expression or prolactin receptor
- 16:26expression uh
- 16:28change the the the the outcome of of
- 16:32balding. And and what we saw was was
- 16:36really really
- 16:38remarkable was that in those that were
- 16:42not balding or had very little balding,
- 16:45they had much lower prolactin receptor
- 16:49levels. And those individuals
- 16:53that had you know moderate to severe
- 16:55balding, you saw an increase in the
- 16:59overall
- 17:02prolactin receptor expression.
- 17:04>> So, to reiterate, Sean's team took
- 17:06genetic data from over 165,000
- 17:09men in a database and then he focused an
- 17:11analysis on genes that control for
- 17:13prolactin receptor expression in cells.
- 17:16Now, some genes will relate to more
- 17:18prolactin receptor expression, others
- 17:20less. And then his team compared those
- 17:23genes to the men's self-reported
- 17:26severities of hair loss, zero being no
- 17:28hair loss, four being severe hair loss.
- 17:31And they found that men with little to
- 17:32no hair loss also happen to have genes
- 17:35linked to lower prolactin receptor
- 17:37expression. And men with lots of hair
- 17:39loss had genes linked to higher
- 17:41prolactin receptor expression, which
- 17:43they also plotted in this chart.
- 17:45>> The thing that's
- 17:46remarkable about this is these are like
- 17:48very, very small changes in prolactin
- 17:51receptor expression.
- 17:54And by very small changes, you're still
- 17:58able to actually see an effect in in
- 18:01male pattern baldness.
- 18:03You know, these aren't massive changes
- 18:04in in overall expression, just minor,
- 18:06minor changes.
- 18:07>> But we know that association doesn't
- 18:09equal causation. Ice cream sales are
- 18:11linked to shark attacks, but ice cream
- 18:13sales do not cause shark attacks. The
- 18:16confounder is the warm weather getting
- 18:18people to buy ice cream, but also to go
- 18:20to the beach and also into the ocean.
- 18:22So, observation by itself is not enough.
- 18:26And then we have to ask, what else is
- 18:28there that might causally link prolactin
- 18:31to androgenic alopecia? Well, even
- 18:32before Absai and Bear thought to target
- 18:35prolactin for androgenic alopecia
- 18:37research, Sean actually told me about a
- 18:39research paper from 2006 by Ralph Paus,
- 18:42and it showed in biopsies of human hair
- 18:45follicles that hair follicles could make
- 18:47prolactin on site and that prolactin
- 18:50could also trigger those hairs to shed.
- 18:53So, that's a little data, but more
- 18:55interesting is some of the mechanistic
- 18:57work that Sean and his team later did to
- 19:00start to tease out cause and effect
- 19:01between prolactin and balding, some of
- 19:04which has not yet been made public until
- 19:06this interview.
- 19:07>> What we did here was we actually took
- 19:10human uh scalp biopsies uh of both male
- 19:13and female and what I'm showing you here
- 19:15is is male. And we then um cultured it
- 19:19in
- 19:20uh with ABS-201 uh which is uh our
- 19:24anti-prolactin receptor um blocking
- 19:26antibody. And uh additionally uh
- 19:30um cultured it with prolactin and then
- 19:32had a rescue arm where we added both
- 19:34prolactin as as well as uh ABS-201. And
- 19:39uh what you see here is uh how much hair
- 19:44uh was grown uh in a 3-day um period and
- 19:48this is, you know, that the same um type
- 19:50of measurement uh that is actually going
- 19:52to be done
- 19:53uh in
- 19:55uh the the clinical study uh looking at
- 19:57um the photography and seeing how much
- 19:59uh hair was actually grown and you can
- 20:01actually see here
- 20:02um within a 3-day time period ABS-201
- 20:07was able to uh increase hair growth. Uh
- 20:10and you you you saw um more hair
- 20:13follicles go into the uh anagen state
- 20:16and um prolactin um when you added it uh
- 20:20essentially shunted the overall growth
- 20:23and by adding both prolactin and uh the
- 20:25the receptor
- 20:27uh
- 20:27or
- 20:28uh or a and and the antibody, you're
- 20:30able to rescue uh the the follicle.
- 20:33>> So here Shawn's team took scalp biopsies
- 20:35from three balding men and then they
- 20:37exposed their skin to either nothing at
- 20:39all or their prolactin receptor antibody
- 20:42drug ABS-201
- 20:44or more prolactin or more prolactin plus
- 20:47ABS-201. Three days later, the samples
- 20:50exposed to ABS-201, they grew longer
- 20:53hair and they still had more of their
- 20:55hairs in the growth phase of their hair
- 20:56cycle than the samples that were left
- 20:58untouched or given more prolactin. The
- 21:00implication from this ex vivo research
- 21:02is that blocking prolactin might improve
- 21:05hair parameters in scalp skin samples of
- 21:07androgenic alopecia. Now, this is great
- 21:09and all, but growing longer hair or
- 21:11having hair is shed less frequently does
- 21:13not explain what happened in these
- 21:15stump-tailed macaques. These monkeys saw
- 21:18near full hair regeneration and near
- 21:20full hair repigmentation.
- 21:23This is a level of recovery that simply
- 21:25does not happen in humans with
- 21:27androgenic alopecia. It also is very
- 21:29rare to see in other monkey studies as
- 21:31well. In fact, in humans in specific,
- 21:33studies show that if you take your DHT
- 21:35as low as you can or you stimulate hair
- 21:38growth with drugs like minoxidil,
- 21:40on average, the best that you can expect
- 21:43is that you'll be able to rewind the
- 21:44clock on how your hair looks by around 6
- 21:47months to 36 months. That's an average.
- 21:49Some people do a little bit better, some
- 21:51people do a little worse, but after that
- 21:54point, it's like people hit a wall. You
- 21:56just don't get more hair back. And the
- 22:00question is why? And at least so far,
- 22:02researchers have identified three
- 22:04possible reasons.
- 22:05First, when you have advanced stages of
- 22:08hair loss, hair follicles will develop
- 22:10scarring or perifollicular fibrosis, and
- 22:12this might act like scaffolding that
- 22:14inevitably blocks hairs from shedding
- 22:16out and then re-sizing as thicker. So,
- 22:18in this case, you can reduce the DHT all
- 22:20you want. You can stimulate the hair to
- 22:21grow all you want, but if you don't get
- 22:23rid of that scaffolding, you're not
- 22:25going to be able to allow for the hairs
- 22:26to re-size as larger in subsequent hair
- 22:28cycles. Second, after hairs become
- 22:31miniaturized beyond a certain point,
- 22:33research suggests that they become
- 22:35detached from their goose bump muscle.
- 22:37That's the arrector pili muscle. And
- 22:39research so far seems to show that while
- 22:41we can save hairs that haven't yet
- 22:42detached from that muscle, we've not yet
- 22:45reliably seen evidence that any
- 22:48treatment available today can re-attach
- 22:50hairs that have detached from the
- 22:52arrector pili. So, hairs that are
- 22:54miniaturized beyond a certain point just
- 22:55don't seem to be able to be saved. And
- 22:58again, reduce all the DHT you want,
- 23:00growth stimulate all you want. If you
- 23:03can't get that attachment back, you're
- 23:04not going to recover those hairs. And
- 23:06the third possibility is that at some
- 23:08point in the balding process, hair
- 23:11follicle stem cells, which tend to be
- 23:13preserved even in advanced stages of
- 23:15hair loss, they start to lose their
- 23:17ability to convert from stem cells to
- 23:19other cell types like progenitor cells.
- 23:22And this failure step is why current
- 23:24treatments might not yet be able to
- 23:26fully revive those miniaturized hairs.
- 23:28And so, for a prolactin receptor
- 23:30antibody to do something like this in
- 23:33humans,
- 23:34that's not coming from hair elongation.
- 23:36It's not coming from a longer growth
- 23:38stage of your hair cycle. That's quite
- 23:40literally hair regeneration. It's taking
- 23:42a fully vellus hair and returning it to
- 23:44a fully terminal hair in many cases.
- 23:46It's solving, somehow, one of these
- 23:49rate-limiting regrowth factors that we
- 23:50know about in androgenic alopecia. And
- 23:52so, I asked Shawn about this and if his
- 23:54team had thought about this. And it
- 23:56turns out they had, and not only had
- 23:58they thought about it, but they had run
- 24:00an experiment, and they think they might
- 24:02actually have identified which of these
- 24:04rate-limiting recovery factors their
- 24:06treatment could address. It's the stem
- 24:08cell failure.
- 24:08>> One of the big things that that you see
- 24:11with
- 24:13balding individuals is that they lose
- 24:16their progenitor
- 24:18cells over time.
- 24:20And as you slowly lose those over time,
- 24:22you get more and more miniaturization
- 24:25that that occurs. Some of the data that
- 24:27that we generated
- 24:29where we were able to see that
- 24:32EBS
- 24:33201
- 24:35is able to
- 24:37actually increase the the proliferation
- 24:40of the K15 stem cell population,
- 24:45and it prevents the apoptosis,
- 24:48which is is really great to to see. You
- 24:51see prolactin on on on the right-hand
- 24:52side
- 24:54does drive apoptosis of the K15
- 24:59stem cell. And what's also really quite
- 25:02interesting
- 25:05is
- 25:07the progenitor
- 25:09cell line. What we see is the CD34 cells
- 25:15are are decreased
- 25:18when you add prolactin
- 25:20to these ex vivo
- 25:23models. Again, these are human
- 25:26scalp biopsies. And so we do believe
- 25:29that blocking prolactin receptor
- 25:33is is able to at least um
- 25:36keep the K15 stem cell population where
- 25:38it is and and be able to stop
- 25:41the CD34
- 25:44stem cell population from further
- 25:47depleting. So we we do think that there
- 25:49is this this ability to actually have a
- 25:51regenerative effect here. Currently,
- 25:55there is no therapy that is able to
- 25:59reverse that that that stem cell niche
- 26:02and, you know, potentially be able to
- 26:04reverse the miniaturization.
- 26:07And this is where we think ABS 201
- 26:10could have a big role.
- 26:13>> Here Shawn is saying that this
- 26:14mechanistic data suggests that if we
- 26:16block prolactin with ABS 201, we might
- 26:19also be able to stop hair follicle stem
- 26:21cell degradation, improve their
- 26:23differentiation into other cell types,
- 26:25and that we might be able to overcome
- 26:27this rate-limiting regrowth factor that
- 26:29other hair loss medications that exist
- 26:31today have failed to address. And that's
- 26:33how we might be able to explain these
- 26:35monkey results. But he also went a step
- 26:37further and he shared data not yet
- 26:39released in any public setting that he
- 26:41feels further corroborates this
- 26:43hypothesis.
- 26:44>> One of the
- 26:46phenotypes that has been shown is that
- 26:49collagen 17A
- 26:51uh
- 26:52over time with the the stem cell Um uh
- 26:55population and
- 26:57collagen 17A is really important uh in
- 27:00the sense that that is what anchors the
- 27:03stem cell population
- 27:05uh to the to the actual hair follicle
- 27:07itself. And what you see is that this
- 27:09gets degraded uh over time. And so the
- 27:13fact that you're actually modulating the
- 27:16stem cells in addition to increasing
- 27:20collagen 17A when blocking the the
- 27:23prolactin receptor uh is is really quite
- 27:27encouraging and and showing that indeed
- 27:30prolactin may sit upstream, you know, uh
- 27:33you know,
- 27:34you know, pretty far upstream where, you
- 27:37know, prolactin is is driving the the
- 27:39degradation of the stem cell niche. It
- 27:41Yeah, it uh you know, drives uh it
- 27:44doesn't replenish the collagen 17A and
- 27:47then it's it's driving the the
- 27:48inflammation that that you see as as
- 27:50well. And so
- 27:52uh we we are encouraged to uh see Again,
- 27:56this is a a 6-day
- 27:59uh culture. So, you you have to kind of
- 28:01take it for what it is, but it is a
- 28:03human biopsy and the the fact that we
- 28:06are seeing results in 6 days is is
- 28:10really incredible. The fact that you're
- 28:11actually regrowing that the hair,
- 28:13showing what prolactin uh you know,
- 28:15showing uh how prolactin
- 28:18uh is driving some of the same
- 28:19phenotypes that that we see
- 28:21uh in in prior research is is really
- 28:24quite exciting. And so you're you're
- 28:26hitting on
- 28:27kind of a
- 28:28a whole different mechanism that both
- 28:31minoxidil as well as uh the, you know,
- 28:34androgen receptor
- 28:36uh um
- 28:37um you know, mechanisms are are unable
- 28:39to uh to to to ultimately address. So,
- 28:43there it is. That's the hypothesis
- 28:45around prolactin and androgenic
- 28:47alopecia. In balding hair follicle
- 28:49sites, prolactin begins to increase.
- 28:52This causes a whole cascade of events.
- 28:54In one cascade, prolactin might increase
- 28:57androgen receptor expression, which then
- 28:59increases DHT, which then damages the
- 29:01hair follicles, causing them to shed
- 29:03prematurely, and then come back
- 29:05miniaturized in the next hair cycle. And
- 29:08simultaneously, in another cascade,
- 29:10prolactin may degrade collagen 17A,
- 29:13which anchors the hair follicle stem
- 29:15cell bulge to the hair follicle itself.
- 29:18And with enough degradation, this then
- 29:20prevents the conversion from hair
- 29:21follicle stem cells into progenitor
- 29:23cells, which then limits our ability to
- 29:25regenerate hair that's already fully
- 29:27miniaturized. Especially with
- 29:28DHT-reducing treatments like finasteride
- 29:30or dutasteride, or even some treatments
- 29:33for females that are more powerful
- 29:34androgen receptor antagonists like
- 29:36spironolactone, flutamide, and
- 29:38bicalutamide. Because these things, they
- 29:40only target part of the equation that
- 29:42Shawn proposes. But by blocking
- 29:44prolactin from reaching the hair
- 29:46follicle at all with a prolactin
- 29:48receptor antibody like ABS-201,
- 29:51Shawn argues that both of these
- 29:53disregulation cascades might get
- 29:56addressed. And that because we're
- 29:58addressing both simultaneously, rather
- 30:00than just one, and we're targeting
- 30:02something further upstream than just
- 30:04DHT, these crazy monkey regrowth results
- 30:07all of a sudden might become a reality
- 30:09for people. And with this model, the
- 30:11monkeys' continued hair regrowth even
- 30:13after quitting treatment becomes at
- 30:15least partly explainable. Because once
- 30:18those stem cell bulge connections are
- 30:20reestablished, hairs might just keep
- 30:22getting thicker and thicker in
- 30:24subsequent hair cycles regardless of
- 30:26whether you're continuing that
- 30:27treatment. Because it also takes time to
- 30:29build them, and it takes time to degrade
- 30:32them as well. So, it's an enticing
- 30:33hypothesis.
- 30:35But then, if the hypothesis is even
- 30:37true, why did HMI 115 fail to regrow
- 30:40hair appreciably in humans? I mean, it
- 30:43barely got any regrowth.
- 30:45Well, this is where Andreas Busch, the
- 30:46man who ran the original HMI 115 studies
- 30:49in monkeys, teams up with Sean and
- 30:52proposes a data-driven conviction. The
- 30:55hypothesis on HMI 115 and prolactin was
- 30:58not wrong.
- 31:00The humans in the study were simply
- 31:02underdosed. And it's this very premise
- 31:05that led Andreas Busch, Sean, and Absi
- 31:08to develop a new drug and rerun this
- 31:10hair loss experiment in humans in what's
- 31:13currently a phase two clinical trial
- 31:15going on right now. Now, here's what
- 31:17Sean had to say about the differences
- 31:19between HMI 115 and ABS-201.
- 31:24There are a lot of technical terms here.
- 31:26I will stop and explain them as we go,
- 31:28but this is the core thesis behind what
- 31:30Sean's company hopes will become a
- 31:32billion-dollar drug.
- 31:34>> What you saw in the stump-tailed
- 31:36macaques was 90% receptor occupancy. And
- 31:42what you saw from the HMI 115 data from
- 31:45the P So, they they publicly released
- 31:47the PK data, and then we modeled the RO
- 31:51based off of of that. And it's it's
- 31:53really quite quite
- 31:55shocking. And yeah, I think you'll
- 31:57you'll you'll see why we're
- 32:00quite confident in the profile that we
- 32:03have.
- 32:03>> Okay, so what is Sean talking about? 90%
- 32:06receptor occupancy, PK data. What does
- 32:08all this mean? Well, first, Sean is
- 32:11referring to what he describes as
- 32:12publicly released pharmacokinetic data
- 32:15on HMI 115. PK stands for
- 32:18pharmacokinetics. That's basically just
- 32:20the study of how a drug behaves in your
- 32:22body. Where it goes, how long it stays
- 32:25there, that kind of stuff. And what Sean
- 32:27is saying is that in this study on
- 32:29monkeys, HMI 115 was able to block 90%
- 32:34of those monkeys' prolactin receptors.
- 32:36In other words, HMI 115 achieved 90%
- 32:39receptor occupancy. And this is
- 32:41important because the more prolactin
- 32:43receptors occupied by HMI 115, the less
- 32:47that prolactin can then attach to that
- 32:49cell, and the less that prolactin can
- 32:51then affect it. So, the more that you
- 32:54block, the less prolactin will have as
- 32:56an influencer on that cell's behavior.
- 32:59And at least in this monkey study, when
- 33:01you hit 90% receptor occupancy for
- 33:04prolactin, it seems to be doing some
- 33:07really impressive things. But, this is
- 33:08the critical point that Shawn is about
- 33:10to make.
- 33:11>> What's really interesting about the
- 33:13prolactin receptor
- 33:16is that you have to block it pretty
- 33:19substantially
- 33:21in order to completely block it. What do
- 33:25I mean by this? Even if you're at, let's
- 33:28say,
- 33:2960, uh, 70, even, you know, 80%
- 33:33um, receptor occupancy, you could still
- 33:35have full activity of the the actual um,
- 33:39pathway until
- 33:41uh, you block it um, you know,
- 33:43substantially.
- 33:44>> Now, what Shawn is talking about here is
- 33:46a concept known as receptor reserves, or
- 33:48spare receptors. Basically, this is a
- 33:51biological phenomenon where for certain
- 33:53hormones, your cells will express a ton
- 33:56of receptors to capture them. Such that
- 33:58a majority of those receptors that are
- 34:00active probably aren't even needed.
- 34:02They're considered spares. One of the
- 34:05most dramatic examples of this is with
- 34:07the hormone insulin. In muscle cells,
- 34:10you can have 100 insulin receptors
- 34:12available, and yet insulin only needs to
- 34:15attach to one of them to exert its
- 34:17maximal metabolic effects on that muscle
- 34:20cell. In other words, it doesn't matter
- 34:22if insulin attaches to just one
- 34:24receptor, or 99 of the receptors. The
- 34:28cell's behavior does not change after
- 34:30one. So, if you wanted to create an
- 34:32insulin receptor blocker that was
- 34:34effective, you'd literally need to find
- 34:36one of that blocked as close to 100% of
- 34:39insulin receptors as possible. Because
- 34:41if the blocker only blocks 99% of them,
- 34:44that medication has zero effect. And it
- 34:46turns out this same receptor reserve
- 34:49relationship may also exist with
- 34:51prolactin. For instance, in one study on
- 34:53lymphoma, prolactin hit its maximal
- 34:57effect on cell growth at just 35%
- 35:00receptor occupancy. So, you could be at
- 35:0235% or 100% and the same growth
- 35:06trajectory occurred. And what this means
- 35:07is that if you made a prolactin receptor
- 35:09blocker that blocked a whopping 65% of
- 35:12prolactin receptors, well, in this
- 35:14lymphoma study, your prolactin receptor
- 35:17blocker would still be 100% useless. In
- 35:20fact, in that study, even if you blocked
- 35:22prolactin receptors by 80%, you'd still
- 35:25see prolactin exerting more than 90% of
- 35:27its maximal growth effect on those
- 35:30cells. So, think of it like failing a
- 35:32test. It doesn't matter if you got a 59
- 35:34out of 100 or a one out of 100, you're
- 35:37still getting an F. And so, now the
- 35:39question becomes with HMI 115, these
- 35:42monkeys were suspected to hit 90%
- 35:45receptor occupancy, RO.
- 35:48But, did the same actually happen in the
- 35:51human clinical trials? According to Sean
- 35:54and Andreas Busch, the answer is no.
- 35:57>> What you see from HMI 115 data here.
- 36:00Again, this was
- 36:02they publicly disclosed what the PK
- 36:05profile was in their phase one. We then
- 36:07modeled out what the RO would be based
- 36:10off of the the publicly available data.
- 36:13And you you see that
- 36:16it takes quite a bit of time
- 36:18for the HMI 115 molecule
- 36:21to actually
- 36:23ramp up to Um, yeah, but 70% uh receptor
- 36:28occupancy is is the the Cmax or 72 73
- 36:32and it then oscillates.
- 36:35Now,
- 36:36what's the significance of the
- 36:38oscillation? So,
- 36:39when you block prolactin receptor, you
- 36:42actually get an increase in prolactin
- 36:44levels.
- 36:46And if you then dip below a certain
- 36:49receptor occupancy threshold, you could
- 36:51actually be activating the the prolactin
- 36:54receptor with the increased levels of
- 36:57prolactin that are in the system. So,
- 37:00you're inadvertently going in between
- 37:03anagen and catagen, anagen catagen,
- 37:05anagen catagen.
- 37:07And we know that it takes time to
- 37:10rebuild the stem cell niche. And you
- 37:12need a sustained
- 37:15uh level of receptor occupancy for a
- 37:18long period of time
- 37:20uh to be able to rebuild that stem cell
- 37:22niche. And we believe this is the reason
- 37:26why uh HMI 115 did not
- 37:30uh achieve the the full efficacy because
- 37:33they they weren't able to give the hair
- 37:36follicle kind of a long enough time to
- 37:39uh actually rebuild that stem cell niche
- 37:41um because it was kind of constantly
- 37:43oscillating in and out of anagen and and
- 37:46catagen um phase versus, you know, what
- 37:48you see with with our molecule is that
- 37:51you get uh sustained levels of greater
- 37:55than 90% receptor occupancy for for 6
- 37:58months uh straight
- 38:00uh and and and we're above the 90%
- 38:03receptor occupancy, which again is what
- 38:05you saw in in the stump tail macaques.
- 38:07And uh again,
- 38:10we believe in the mechanism based on
- 38:12everything we've we've told you.
- 38:14It just came down to a PK inducing issue
- 38:18with HMI 115. So, now you have the core
- 38:21thesis behind ABS201. Andreas, Shawn,
- 38:24the broader Absite team, they developed
- 38:26this drug to solve for this receptor
- 38:28occupancy problem. And their phase one
- 38:31and pharmacokinetic studies, according
- 38:32to Shawn, prove that ABS201 achieves a
- 38:36prolactin receptor occupancy level of
- 38:39greater than 90%. That's a lot. And
- 38:41being above that 90% receptor occupancy
- 38:44threshold, according to Shawn through
- 38:46inferences in this monkey data, is the
- 38:48level that you need to adequately
- 38:50suppress prolactin levels in hair
- 38:51follicles. Which, with sustained
- 38:54suppression, will hopefully give the
- 38:56stem cell bulge enough time to rebuild,
- 38:58which is what we need to achieve truly
- 39:00regenerative effects in humans. And it's
- 39:03this very premise that guided Shawn's
- 39:06team through preclinical work, then
- 39:08phase one human studies for safety, and
- 39:10now a phase two human study on men and
- 39:14women with androgenic alopecia. And
- 39:16this, Shawn believes, is the test that
- 39:19we need to truly ascertain if this
- 39:21hypothesis surrounding prolactin and
- 39:23hair holds validity. And if this
- 39:26treatment target might be the
- 39:28breakthrough the entire hair loss
- 39:29community has been waiting for. This
- 39:31phase two study, it is already underway,
- 39:33and in December of this year, Shawn and
- 39:36his team plan to do a preliminary
- 39:3813-week read and an announcement of the
- 39:41data.
- 39:42>> The 13-week data read out that's going
- 39:44to come in December. We have not given
- 39:48firm metrics on what we would like to
- 39:50achieve there. We have talked about it
- 39:53being directional. We want to see that
- 39:55the mechanism is is is working and that
- 39:57there is kind of a path to
- 40:0030 plus hairs per square centimeter at
- 40:02at at 26 week. And so, I think that we
- 40:05have set ourselves up
- 40:07in a way that again, this is a more an
- 40:09exploratory look at how the mechanism is
- 40:14is performing to to to
- 40:18Additionally,
- 40:19we do feel good about the readout at 26
- 40:23weeks, but
- 40:25let's say we achieve a 30 plus
- 40:28at 26 weeks. My guess is that
- 40:329 12 months, you continue to see an
- 40:35increase from from there. But, you know,
- 40:38we are confident
- 40:40that
- 40:42you'll see, I think, strong or good
- 40:46results at at at 26 weeks, but that
- 40:48doesn't take away from the fact that you
- 40:50could continue to see
- 40:52hair regrowth past
- 40:546 months. And And the great part about
- 40:56that is we are actually going to be
- 40:58tracking these patients for a year post
- 41:01treatment. So, we are going to
- 41:02understand like how
- 41:05the you know, how how the changes are
- 41:08are progressing over over that year post
- 41:11treatment. So, I think that that'll also
- 41:13be a really exciting
- 41:14insight that we're going to see as well.
- 41:16>> And here's the part that I really
- 41:17appreciated about my conversation with
- 41:19Shawn. So, I voiced to him about how
- 41:22frustrated I've been this year and last
- 41:24year with all of the press releases from
- 41:25other companies that are pursuing future
- 41:27hair loss treatments.
- 41:28The through line here is that there is a
- 41:31massive amount of data withholding,
- 41:33manipulation of statistics, disingenuous
- 41:35comparisons across hair count groups,
- 41:37subgroup of subgroup analyses, the
- 41:39absence of reporting of critical metrics
- 41:41like absolute terminal hair count
- 41:42changes. And so, I just asked him
- 41:44directly that regardless of these
- 41:4513-week results, if it would be possible
- 41:48if he could commit to just not pulling
- 41:50any of these weird statistical stunts or
- 41:52obscurities in the way that data is
- 41:54reported. And here is what he said.
- 41:56>> I can promise you that we will have a
- 41:59non-controversial
- 42:01data cut. We are not going to do a
- 42:02subpopulation of subpopulation like it
- 42:05it's going to be
- 42:06clear-cut uh
- 42:08data that will be
- 42:11uh to to interpret. And that to me is
- 42:13amazing news. So, kudos to Shawn for
- 42:16this, and in December or January, you
- 42:18can bet that I'll be making a follow-up
- 42:19video about that press release and the
- 42:22data. I hope that it is fantastic.
- 42:25So, this about wraps the steel man case
- 42:27for prolactin, its role or potential
- 42:30role in androgenic alopecia, HMI 115,
- 42:33why it supposedly failed, the evolution
- 42:35to ABS-201, and how lowering prolactin
- 42:38might unlock near full levels of hair
- 42:40regrowth. And I really want to present
- 42:42Shawn and the broader data here in the
- 42:44strongest way possible. I wanted to slow
- 42:46down the storytelling to reiterate
- 42:48information that was key, to add support
- 42:50where I could, because he reached out to
- 42:53us. He gave me a ton of time. We had two
- 42:55calls. The first one was an hour, the
- 42:57second one was two hours. He's committed
- 42:59to giving public an uncontroversial
- 43:01reads of ABS-201's 13-week data.
- 43:04And that part of the discussion here
- 43:06deserves to stand alone without my
- 43:08interruptions, without my nitpicking,
- 43:10because it truly is a service that Shawn
- 43:12took the time to do this. But I
- 43:13obviously asked Shawn a ton of questions
- 43:15during our conversations, because I
- 43:17wanted to improve my clarity on the
- 43:19strengths, but also the limitations of
- 43:21the evidence presented. And in this
- 43:22respect, I always think that we should
- 43:24remain hopeful about future treatments
- 43:26and the work going into them. But in
- 43:28general, it usually helps to have a
- 43:31precaution to temper expectations about
- 43:34what a clinical trial is going to do,
- 43:36because
- 43:37as it stands, I think the data around
- 43:39prolactin and hair loss is compelling in
- 43:41some respects and limited and
- 43:44potentially conflicting in others. And
- 43:46I'll get into that level by level right
- 43:48now.
- 43:50First, let's start off with HMI 115's
- 43:53monkey data.
- 43:54The results are absolutely incredible. I
- 43:56mean it when I say that I've never seen
- 43:58monkey results to this degree, and the
- 44:00continued hair regrowth post-treatment
- 44:02withdrawal, I have never seen that in
- 44:04any androgenic alopecia study, monkey or
- 44:06human, before. But, is this magnitude of
- 44:08regrowth truly unrivaled in monkey
- 44:10studies? Not necessarily. While it's not
- 44:13the same recovery, take a look at this
- 44:16study on stump-tailed macaques and
- 44:17minoxidil. In humans, topical minoxidil
- 44:20tends to produce relatively modest hair
- 44:22gains. The cosmetic results tend to peak
- 44:24around 6 to 8 months, and then you
- 44:26plateau and even slowly decline
- 44:28thereafter.
- 44:29But, in this monkey study, the monkeys
- 44:31using minoxidil, they just kept
- 44:34regrowing hair. They regrew hair at
- 44:35month three, at month six, and at month
- 44:37nine. In fact, they kept regrowing more
- 44:39and more hair all the way up until they
- 44:41withdrew from treatment. So, these
- 44:43monkey models can directionally
- 44:45translate to humans with androgenic
- 44:47alopecia. But, they're not perfect
- 44:50surrogates by any means. In fact, in my
- 44:51opinion,
- 44:53I think that reconverting vellus hairs
- 44:55into terminal hairs in monkeys is just a
- 44:57ton easier than it is in humans because
- 44:59the treatments that seem to do it in
- 45:00monkeys, like minoxidil, when you apply
- 45:03those to humans, you don't get the same
- 45:05results. You get the same directional
- 45:08results, you don't get the same
- 45:10magnitude of results. And it's not just
- 45:13minoxidil. We've also seen the magnitude
- 45:15of results really decrease with other
- 45:17treatments. When latanoprost or
- 45:19bimatoprost moved from monkey models to
- 45:22humans, they went from pretty impressive
- 45:25results to very tiny, ambiguous, and
- 45:28cosmetically insignificant results. So
- 45:31again, we have to temper our
- 45:33expectations. What we see in these
- 45:34monkeys directionally might fit with
- 45:36humans, but the magnitude of impact, it
- 45:38might be very tiny. We don't know yet.
- 45:42Next, let's talk about this genetic data
- 45:44that Shawn presented. Now, Shawn showed
- 45:45us some charts suggesting that genes
- 45:47linked to higher prolactin receptor
- 45:48expression were also linked to higher
- 45:51severities of balding. And Shawn noted
- 45:53in the interview that all it took were
- 45:55just tiny differences in prolactin
- 45:57receptor expression to show this
- 45:59relationship in the severities of
- 46:01balding. However, this observational
- 46:03relationship to me appears somewhat at
- 46:06odds with the idea that prolactin is a
- 46:08hormone with high spare receptors or
- 46:11receptor reserves. So, for instance, if
- 46:15this gene for prolactin receptor
- 46:16expression is linked to little to no
- 46:18hair loss, but this gene is linked to a
- 46:21ton of hair loss. And yet, the
- 46:23difference in prolactin receptor
- 46:24expression across the genes is maybe 10,
- 46:2720, 30, 50, 70% even if it's 80%.
- 46:31Then what difference does that make if
- 46:33all prolactin needs to do to trigger
- 46:35hair loss is occupy 10% of those
- 46:39available prolactin receptors? With such
- 46:41a low threshold for prolactin to
- 46:42potentially have these adverse hair
- 46:44effects, wouldn't that imply that micro
- 46:47differences in prolactin receptor
- 46:48expression shouldn't matter at all? That
- 46:50instead, we would want to see 10 or
- 46:5220-fold differences in expression
- 46:54activity before we start to see these
- 46:56problems?
- 46:58And yet, we can't really answer these
- 46:59questions right now because the data is
- 47:01so preliminary, but it's also really
- 47:03limited.
- 47:05Next, let's talk about some of the ex
- 47:07vivo data that Shawn presented. These
- 47:09studies on balding hair follicles are
- 47:11great mechanistic tools for research.
- 47:14But the one relationship that they don't
- 47:16establish is if all these same
- 47:18directional relationships with hair also
- 47:22exist in non-balding scalp hair. Because
- 47:25if prolactin also does all the same
- 47:27exact things at the same exact
- 47:29magnitude. It stops hair elongation. It
- 47:32turns hairs from growing into resting.
- 47:35If it does that the same in balding hair
- 47:37samples as it does in non-balding hair
- 47:40samples, then this would actually weaken
- 47:42the case for prolactin causing
- 47:44androgenic alopecia. So, I asked Shawn
- 47:46about this in the interview and if they
- 47:47had done experiments with non-balding
- 47:49human scalp hair as well. And here was
- 47:51his response.
- 47:52>> Really quickly, so we can see that
- 47:54there's some degree of significance with
- 47:57those effect sizes on the slides you
- 47:59just showed. Those are from three male
- 48:01scalp biopsies with androgenic alopecia.
- 48:04Do you have control data on a scalp
- 48:07unaffected by androgenic alopecia as a
- 48:09comparator of any type?
- 48:11>> Uh
- 48:12we do not. We took it from an androgen
- 48:14sensitive uh area, uh
- 48:17which is the frontal temporal uh region.
- 48:20Um but we did not have a
- 48:25uh healthy or a
- 48:27um
- 48:28non uh
- 48:30um
- 48:31you know, balding sensitive uh area. Um
- 48:35so so we currently do not have that at
- 48:36the moment.
- 48:37>> Okay. Yeah, I'd be really curious to see
- 48:39if you see the same exact drops in an
- 48:43unaffected AGA scalp skin sample as
- 48:45well. Because then that would help to
- 48:47tease out whether or not those drops are
- 48:48truly relevant to the mechanisms being
- 48:51explored.
- 48:52>> Yeah, absolutely. And uh one of the
- 48:55things that I think will will will see
- 48:58uh actually before we even get data like
- 48:59that is actually how this performs in in
- 49:01in humans later this year.
- 49:03>> Now, for what it's worth, Shawn's reply
- 49:05here is fair. You could spend your whole
- 49:08life running ex vivo studies trying to
- 49:10guess what happens in a human.
- 49:11Eventually, you just need to prove
- 49:13safety as best as you possibly can and
- 49:15move on to human testing. But without
- 49:17those non-balding control samples, I
- 49:19personally don't find this mechanistic
- 49:21data nearly as compelling. And the same
- 49:24criticisms apply to research presented
- 49:26about collagen 17A. It's a fascinating
- 49:29hypothesis, new research indicates this
- 49:31could be a critical piece to the balding
- 49:33process, and a rate-limiting recovery
- 49:35factor with respect to androgenic
- 49:37alopecia treatment success. But without
- 49:39knowing how non-balding hairs also react
- 49:42and also express collagen 17A, we can't
- 49:45actually distinguish if any increased
- 49:48expression or decreased expression of
- 49:50anything is meaningful and if it's truly
- 49:53unique just to balding affected skin.
- 49:56And this matters even more when we
- 49:58actually revisit that original 2006
- 50:00paper from Ralph Paus. And we actually
- 50:02see that in that study the effects of
- 50:05prolactin on human hair follicles, they
- 50:08were coming from non-balding hair
- 50:10follicles. And yet the researchers found
- 50:12the same relationships.
- 50:14This study used occipital regions of the
- 50:17scalp during facelifts and hair
- 50:19transplant surgeries. And in both cases
- 50:21those should be hairs that are
- 50:22relatively protected from the balding
- 50:24process that aren't as prone to DHT's
- 50:27mediating effects on androgenic
- 50:28alopecia. And yet in that 2006 study,
- 50:31the same relationship seemed to exist
- 50:33with a non-balding human hair follicle
- 50:35as we're now seeing in the balding human
- 50:37hair follicle research 20 years later.
- 50:41Next, there's the discussion about
- 50:43safety, about lowering prolactin levels
- 50:46in cells and whether or not that's
- 50:47something that's safe long-term.
- 50:50In women, hyperprolactinemia is
- 50:52associated with an inability to lactate
- 50:54and it's also associated with
- 50:55infertility. Now on their own website,
- 50:57Absi sites papers to suggest that
- 51:01reducing prolactin is potentially very
- 51:03safe for many adverse events.
- 51:06But they mainly focus on safety metrics
- 51:08that are not fertility and not
- 51:09lactation. And because of this I wanted
- 51:11to understand not only which adverse
- 51:14events of interest Shawn's team will be
- 51:16tracking in their clinical study, I also
- 51:18wanted to know how they were tracking
- 51:20the adverse events themselves. And
- 51:23there's a very specific reason why I
- 51:24wanted to ask this. I will show you the
- 51:26clip here.
- 51:27>> You mentioned Veridermis just a second
- 51:29ago. I've been tracking their data as
- 51:31well. I think that anybody innovating
- 51:33and attempting to run
- 51:35well-designed studies in the hair loss
- 51:37space for interventions is incredible.
- 51:40So I really appreciate what they're
- 51:41trying to do. When I looked at their
- 51:45clinical data and specifically their
- 51:46adverse events. I saw some things that
- 51:49didn't make total sense to me. So, we
- 51:51know that their formulation is
- 51:54uh
- 51:55a larger dose of minoxidil that is
- 51:56supposed to slowly leak into your system
- 51:58over time.
- 51:59>> [snorts]
- 52:00>> And when we look at all of the clinical
- 52:02studies on oral minoxidil ranging from
- 52:040.25 mg and higher, 60%
- 52:09of participants, both male and female,
- 52:11across literally all of the studies
- 52:13report hypertrichosis.
- 52:15And when I looked at Verodermal safety
- 52:16data, I saw the hypertrichosis numbers
- 52:19at something like 3 to 6% which was
- 52:22comparable to the placebo group. So,
- 52:24this means that either they have
- 52:26inadvertently developed a hyper-targeted
- 52:28oral minoxidil that then attaches only
- 52:31to the scalp and does not affect hair
- 52:33anywhere else on the body, which is not
- 52:35listed in any of their patents,
- 52:37or there is something with their data
- 52:40collection with respect to safety that
- 52:42is not adequately capturing the real
- 52:44risk of hypertrichosis that we would
- 52:46expect for this medication, which then
- 52:48leads me to the question about how your
- 52:50team in your phase two clinical studies
- 52:52is capturing clinical adverse events
- 52:55reporting.
- 52:56Are these done through interviews with
- 52:58the investigators? Are these done
- 53:01through survey systems? Are they done
- 53:03through open-ended questionnaires? Each
- 53:05of these has their pros and their cons
- 53:07and there's plenty of debate as to which
- 53:09is the best in clinical research and
- 53:11reporting, but I'm curious just to get
- 53:13your perspective on how you are tracking
- 53:15these things earlier we were talking
- 53:17about libido and the potential for no
- 53:21effect, maybe even benefit from this
- 53:24type of therapy,
- 53:25but then libido is separate from semen
- 53:28parameters and you can have a strong
- 53:29libido and be completely infertile. And
- 53:32so, I'm just kind of curious at this
- 53:33point for how you guys in your phase two
- 53:35clinical research have pre-specified how
- 53:37you'll collect adverse events and the
- 53:39specific adverse events that you are
- 53:41exploring.
- 53:43>> Yeah, it's a great question. So, first
- 53:45off, we have a fantastic chief medical
- 53:49officer. Uh he was the the SVP and head
- 53:54of clinical development at Vertex. Prior
- 53:57to that, he was at
- 53:59Amgen and you know, has you know,
- 54:0120-plus years of
- 54:03very hardcore clinical development
- 54:06experience
- 54:07at you know, well outside of even you
- 54:09know, he's he's run some of the most
- 54:11complex and and hard clinical trials. He
- 54:14actually ran a you know, the Jornavik's
- 54:16the the NAV 1.8 clinical study, which is
- 54:20a pain study. And pain studies are
- 54:22notoriously very very challenging and
- 54:25and was successful in in that study. And
- 54:28so, he has brought a lot of rigor into
- 54:33Absai on the clinical development side.
- 54:36And we are wanting to make sure that we
- 54:39have a robust
- 54:42study. And you know, we believe with how
- 54:45we have set up this study, if
- 54:48successful, we see this as a
- 54:50potentially a dose range finding study,
- 54:53where we can go on to a phase three
- 54:56clinical study. And and in terms of like
- 54:59the overall clinical operations, the
- 55:01protocols that that we have in in place,
- 55:04I can say that they're of the the
- 55:05highest standard. And
- 55:09you know, these
- 55:10you know, the the questionnaires and and
- 55:11how they're asked, they're they're all
- 55:13done
- 55:14in a way to really help
- 55:17do it in an unbiased
- 55:19way. And and we have a really incredible
- 55:22clinical development team. On all the
- 55:24specific you know, details,
- 55:26we'd have to bring him on to to kind of
- 55:28go through all of those. But I I I do
- 55:31know though that
- 55:33it is a is a very rigorous study. And
- 55:36you know, you can even look at how we
- 55:38designed the the phase two clinical
- 55:40study. It's a, you know, it's a three to
- 55:42one
- 55:43um,
- 55:45placebo
- 55:47controlled
- 55:48double-blinded study,
- 55:51and yeah, really excited about the the
- 55:53overall
- 55:55kind of results both on the efficacy as
- 55:58well as being able to ensure that the
- 56:01you know, adverse
- 56:02events are are
- 56:04recorded and and
- 56:06done in an appropriate manner.
- 56:07>> By the way, I'll link our video on
- 56:09Veridermics below if you caught that
- 56:10comment. But in any case, Shawn
- 56:12preferred in this case to defer
- 56:14answering this to his head of clinical
- 56:16development.
- 56:17Also, it is totally fine to do that.
- 56:19He's the CEO of Absi. He's not in the
- 56:22weeds leading every aspect of the
- 56:24clinical research projects. But adverse
- 56:26event tracking and how it's reported is
- 56:28one piece of a clinical trial protocol
- 56:31that basically almost never gets
- 56:33published publicly in a repository, but
- 56:35that is super important to understand
- 56:38because the way that you collect results
- 56:40can drastically change the outcomes. And
- 56:42those differences in results don't
- 56:44actually reflect product safety
- 56:45differences. They just reflect
- 56:46differences in the way that data was
- 56:48collected, and that's the issue. So
- 56:50perhaps in the future we can get a
- 56:51little bit better clarity on this, and
- 56:53it'll be one of the things that I'd love
- 56:55to focus on if and when it's time to see
- 56:57Absi's clinical data or if we're able to
- 56:59connect with their head of clinical
- 57:01research.
- 57:03Next, for veterans of the hair loss
- 57:05community, you will know that we have
- 57:07reached this milestone in research for
- 57:10hair loss treatments many times before.
- 57:12Where observational, mechanistic, and
- 57:14even early interventional data all point
- 57:17toward a new novel breakthrough just
- 57:20around the corner for androgenic
- 57:21alopecia, only for the human clinical
- 57:23trial to fail miserably.
- 57:25One recent example, prostaglandin D2
- 57:28antagonism. Specifically, the drug
- 57:31setipiprant.
- 57:32Observational data found that
- 57:34prostaglandin D2 was elevated in balding
- 57:36scalps. Mechanistic data suggested PGD2
- 57:39stopped hair lengthening. Monkey data on
- 57:41prostaglandin analogs like latanoprost,
- 57:44bimatoprost, even to a certain extent
- 57:46minoxidil, all showed impressive hair
- 57:49gains. And yet, when a prostaglandin D2
- 57:51inhibitor setipiprant was finally tested
- 57:54in men with androgenic alopecia,
- 57:56there was literally no effect at all.
- 57:58So, remain hopeful, but don't forget
- 58:02about the graveyard of prior prospective
- 58:04treatments that made it all the way to
- 58:07this point, only to still fail a
- 58:09clinical trial. Statistically, it is the
- 58:12phase two human study that tends to make
- 58:15or break most real contenders in the
- 58:18hair loss treatment space.
- 58:20And lastly, this one I really love. Even
- 58:23if ABS-201 fails, it still actually does
- 58:27not disprove the hypothesis that
- 58:29prolactin might be a root cause of
- 58:31androgenic alopecia. It might turn out
- 58:33that it's still just not powerful enough
- 58:35of a prolactin receptor antibody. Keep
- 58:38in mind that that lymphoma study I
- 58:40talked about earlier, even when
- 58:41prolactin occupied just 7% of the
- 58:44available receptors, cell growth was
- 58:47still at 50% its maximal speed. In this
- 58:50respect, we might actually find that a
- 58:51failed clinical trial on ABS-201 simply
- 58:54means that we have to build something
- 58:55that suppresses prolactin even harder.
- 58:57It's wild to think about that fact that
- 59:00even with ABS-201, a drug that was
- 59:02designed to overcome this one liability,
- 59:04we still might not be able to confirm or
- 59:07rule out the legitimacy of the
- 59:08hypothesis. And that is just the way
- 59:11that hair loss research goes.
- 59:14Okay, that is everything. I know this
- 59:16video was a long one. I hope that you
- 59:18enjoyed it. I hope that you learned
- 59:19something. We put a ton of time into
- 59:21creating it. And I really wanted to
- 59:23thank Shawn for taking the time to reach
- 59:25out and do this interview with us. I
- 59:27loved our discussion. I really
- 59:29appreciated his time and most
- 59:31importantly, I want his product to
- 59:33succeed. I think that if it does, it's
- 59:35going to be an incredible compliment or
- 59:37even a replacement to every other
- 59:39treatment out there. We can only hope
- 59:42and time will only tell. We'll know more
- 59:44at that 13-week data read. However, even
- 59:47if the results are very tiny at 13
- 59:49weeks, recall that the monkeys took 4
- 59:52years for significant hair regeneration.
- 59:55You can't look at the data at 13 weeks
- 59:57for efficacy. I think that would be a
- 59:59huge mistake. What we should be looking
- 1:00:02at here is whether or not the prolactin
- 1:00:04receptor antibodies are safe. What are
- 1:00:07people reporting in terms of fertility
- 1:00:10markers, libido markers, anything else
- 1:00:13that's an adverse event of interest?
- 1:00:15That is what's most important at this
- 1:00:17read. Even if hair counting data looks
- 1:00:20flat or slightly negative, I am not
- 1:00:22discouraged by that. It is 13 weeks. So,
- 1:00:25give it more time. Speaking of time, if
- 1:00:27you are fighting hair loss, you have to
- 1:00:29make do with the treatments that are
- 1:00:31available today. And if you're
- 1:00:33interested in pursuing treatments that
- 1:00:35are hyper-personalized and
- 1:00:36evidence-based, I helped co-found the
- 1:00:38brand ULO, that's ulo.co,
- 1:00:42to facilitate access to those
- 1:00:43treatments. We're US-based telehealth
- 1:00:46brand focused exclusively on hair loss
- 1:00:49and we deliver what I would consider an
- 1:00:50unrivaled level of personalization to
- 1:00:53make sure you're getting the best
- 1:00:54possible outcomes that respect your
- 1:00:56needs, but also your preferences. We
- 1:00:58have low-dose formulations of topical
- 1:00:59finasteride and topical dutasteride,
- 1:01:02their full-strength counterparts. We
- 1:01:04have topical minoxidils paired with
- 1:01:06retinoic acid or tretinoin. We offer
- 1:01:08high-strength oral dutasteride,
- 1:01:10standard-dose oral dutasteride,
- 1:01:12standard-dose finasteride, and a lot of
- 1:01:15other options to help facilitate your
- 1:01:17journey. I hope you check out the brand
- 1:01:18and in the meantime, we'll keep making
- 1:01:20content like this. I hope you enjoy it.
- 1:01:22I look forward to next time.
About this transcript
This page contains the full transcript of Prolactin Is THE Root Cause of Hair Loss?! Absci’s New Drug May Prove It by Perfect Hair Health, generated from the public captions YouTube serves with the video. The transcript has 9,752 words across 1,598 segments, with the original timestamps preserved so you can click any line to jump to that moment in the embedded player.
What you can do with it
Use the transcript to take notes, quote the speaker, build a study guide, generate a summary with ChatGPT or Claude via the YouTube Summary tool, or export it as a timed subtitle file with YouTube to SRT. You can also re-open it in the transcriber to choose a caption track available on the video.
Free YouTube transcript tool
YouTube2Text is a free YouTube transcript generator — no signup, no daily limit. Paste any YouTube link and get the full transcript instantly, with timestamps, click-to-jump, caption language selection, AI prompts for ChatGPT, Claude, and Gemini, and exports to TXT, SRT, VTT, or Markdown.